Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Kaiser Permanente Colorado
1960 North Ogden Street, Denver, CO 80218
1707 E. Charleston Blvd. Suite 230, Las Vegas, NV 89102
University of Utah
50 N Medical Drive,, Salt Lake City, UT 84132
Regional West Health Services
3911 Ave. B, Suite 1110, Scottsbluff, NE 69361
Advanced Research Institute
6028 South Ridgeline Drive, South Ogden, UT 84405
660 S. Euclid, St. Louis, MO 63110
Tripler Army Medical Center
1 Jarrett White Rd, Tripler Army Medical Center, HI 96859
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.